Nadir of platelets, hemoglobin, and lymphocytes and highest ALAT value after high-dose methotrexate and relation to RFC80 polymorphism in low-risk ALL patients
| Reduced folate carrier, genotype . | AA . | GA . | GG . | Ratio (95% CI) . | P . |
|---|---|---|---|---|---|
| Platelets, ×109/L | |||||
| Patients | 29 | 72 | 39 | ||
| HDMTX courses | 116 | 279 | 153 | ||
| Mean (geometric) | 73 | 99 | 105 | ||
| CI | 55-95 | 78-125 | 81-136 | ||
| GG versus AA | 1.44 (1.14-1.82) | .002 | |||
| GA versus AA | 1.36 (1.10-1.68) | .004 | |||
| GG versus GA | 1.06 (.88-1.28) | .546 | |||
| Time to count recovery (> 150) after first HDMTX in days, geometric mean | 3.4 | 2.4 | 2.4 | ||
| Hemoglobin, mmol/L | |||||
| Patients | 29 | 72 | 39 | ||
| HDMTX courses | 116 | 279 | 153 | ||
| Mean (geometric) | 5.6 | 5.9 | 6.0 | ||
| CI | 5.4-5.8 | 5.7-6.1 | 5.8-6.2 | ||
| GG versus AA | 1.06 (1.02-1.10) | .001 | |||
| GA versus AA | 1.05 (1.01-1.08) | .004 | |||
| GG versus GA | 1.01 (.98-1.04) | .395 | |||
| Neutrophils, ×109/L | |||||
| Patients | 28 | 72 | 38 | ||
| HDMTX courses | 111 | 262 | 149 | ||
| Mean (geometric) | 0.7 | 0.8 | 0.8 | ||
| CIl | 0.6-0.9 | 0.7-1.0 | 0.7-0.9 | ||
| GG versus AA | 1.07 (.86-1.32) | .551 | |||
| GA versus AA | 1.11 (.92-1.35) | .286 | |||
| GG versus GA | .96 (.81-1.14) | .652 | |||
| Time to count recovery (> 0.5) after first HDMTX in days, geometric mean | 4.4 | 3.4 | 2.4 | ||
| ALAT, U/L | |||||
| Patients | 28 | 71 | 38 | ||
| HDMTX courses | 102 | 227 | 132 | ||
| Mean (geometric) | 123.8 | 127.0 | 167.1 | ||
| CI | 86-177 | 93-174 | 119-236 | ||
| GG versus AA | 1.35 (1.00-1.82) | .049 | |||
| GA versus AA | 1.02 (.78-1.34) | .851 | |||
| GG versus GA | 1.31 (1.03-1.69) | .030 |
| Reduced folate carrier, genotype . | AA . | GA . | GG . | Ratio (95% CI) . | P . |
|---|---|---|---|---|---|
| Platelets, ×109/L | |||||
| Patients | 29 | 72 | 39 | ||
| HDMTX courses | 116 | 279 | 153 | ||
| Mean (geometric) | 73 | 99 | 105 | ||
| CI | 55-95 | 78-125 | 81-136 | ||
| GG versus AA | 1.44 (1.14-1.82) | .002 | |||
| GA versus AA | 1.36 (1.10-1.68) | .004 | |||
| GG versus GA | 1.06 (.88-1.28) | .546 | |||
| Time to count recovery (> 150) after first HDMTX in days, geometric mean | 3.4 | 2.4 | 2.4 | ||
| Hemoglobin, mmol/L | |||||
| Patients | 29 | 72 | 39 | ||
| HDMTX courses | 116 | 279 | 153 | ||
| Mean (geometric) | 5.6 | 5.9 | 6.0 | ||
| CI | 5.4-5.8 | 5.7-6.1 | 5.8-6.2 | ||
| GG versus AA | 1.06 (1.02-1.10) | .001 | |||
| GA versus AA | 1.05 (1.01-1.08) | .004 | |||
| GG versus GA | 1.01 (.98-1.04) | .395 | |||
| Neutrophils, ×109/L | |||||
| Patients | 28 | 72 | 38 | ||
| HDMTX courses | 111 | 262 | 149 | ||
| Mean (geometric) | 0.7 | 0.8 | 0.8 | ||
| CIl | 0.6-0.9 | 0.7-1.0 | 0.7-0.9 | ||
| GG versus AA | 1.07 (.86-1.32) | .551 | |||
| GA versus AA | 1.11 (.92-1.35) | .286 | |||
| GG versus GA | .96 (.81-1.14) | .652 | |||
| Time to count recovery (> 0.5) after first HDMTX in days, geometric mean | 4.4 | 3.4 | 2.4 | ||
| ALAT, U/L | |||||
| Patients | 28 | 71 | 38 | ||
| HDMTX courses | 102 | 227 | 132 | ||
| Mean (geometric) | 123.8 | 127.0 | 167.1 | ||
| CI | 86-177 | 93-174 | 119-236 | ||
| GG versus AA | 1.35 (1.00-1.82) | .049 | |||
| GA versus AA | 1.02 (.78-1.34) | .851 | |||
| GG versus GA | 1.31 (1.03-1.69) | .030 |
P values are adjusted for repeated measurements.
ALAT indicates alanine aminotransferase; CI, confidence interval; and HDMTX, high-dose methotrexate.